# Study Evaluating Pantoprazole in Children With GERD

> **NCT00141817** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 41 (actual)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DRUG:** pantoprazole for approximately 9 weeks.

## Key facts

- **NCT ID:** NCT00141817
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2011-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141817, "Study Evaluating Pantoprazole in Children With GERD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00141817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*